ERAB (E135) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
ERAB (E135) Peptide Applications :
Blocking Background :
β-Amyloid is a neurotoxic peptide that is associated with the pathogenesis of Alzheimer’s disease. β-Amyloid aggregates induce cell death of neurons through the disruption of cell membranes and the generation of reactive oxygen intermediates.These neurotoxic effects are also attributed to the interaction of β-Amyloid with intracellular proteins, specifically ERAB, the endoplasmic reticulum-associated β-Amyloid-binding protein. ERAB is characterized as a NAD+-dependent dehydrogenase that is constitutively expressed in tissues and overexpressed in neurons affected in Alzheimer’s disease. Cells overexpressing ERAB in vitro have been shown to be more sensitive to β-Amyloid-induced stress, and blocking the activity of ERAB has been shown to inhibit this cell death, indicating that β-Amyloid induced cell death is mediated by ERAB. Alternative Name :
3-hydroxyacyl-CoA dehydrogenase type-2; EC=1.1.1.35; 17-beta-hydroxysteroid dehydrogenase 10; 17-beta-HSD 10; 3-hydroxy-2-methylbutyryl-CoA dehydrogenase; EC=1.1.1.178; 3-hydroxyacyl-CoA dehydrogenase type II; Endoplasmic reticulum-associated amyloid beta-peptide-binding protein; Mitochondrial ribonuclease P protein 2; Mitochondrial RNase P protein 2; Short-chain type dehydrogenase/reductase XH98G2; Type II HADH; ERAB; HADH2; MRPP2; SCHAD; XH98G2; HSD17B10 Swiss-Prot :
Q99714 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide ERAB (E135). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1713 ERAB (E135) pAb.
ERAB (E135) Peptide Applications :
Blocking Background :
β-Amyloid is a neurotoxic peptide that is associated with the pathogenesis of Alzheimer’s disease. β-Amyloid aggregates induce cell death of neurons through the disruption of cell membranes and the generation of reactive oxygen intermediates.These neurotoxic effects are also attributed to the interaction of β-Amyloid with intracellular proteins, specifically ERAB, the endoplasmic reticulum-associated β-Amyloid-binding protein. ERAB is characterized as a NAD+-dependent dehydrogenase that is constitutively expressed in tissues and overexpressed in neurons affected in Alzheimer’s disease. Cells overexpressing ERAB in vitro have been shown to be more sensitive to β-Amyloid-induced stress, and blocking the activity of ERAB has been shown to inhibit this cell death, indicating that β-Amyloid induced cell death is mediated by ERAB. Alternative Name :
3-hydroxyacyl-CoA dehydrogenase type-2; EC=1.1.1.35; 17-beta-hydroxysteroid dehydrogenase 10; 17-beta-HSD 10; 3-hydroxy-2-methylbutyryl-CoA dehydrogenase; EC=1.1.1.178; 3-hydroxyacyl-CoA dehydrogenase type II; Endoplasmic reticulum-associated amyloid beta-peptide-binding protein; Mitochondrial ribonuclease P protein 2; Mitochondrial RNase P protein 2; Short-chain type dehydrogenase/reductase XH98G2; Type II HADH; ERAB; HADH2; MRPP2; SCHAD; XH98G2; HSD17B10 Swiss-Prot :
Q99714 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide ERAB (E135). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1713 ERAB (E135) pAb.
Blocking peptide available as BS1713PP